Janssen Biotech, Inc.

TECVAYLI

Manufacturer:

Janssen Biotech, Inc.

Tecvayli HCPCS:

J9380

HCPCS Code Descriptor:

Injection, teclistamab-cqyv, 0.5 mg

Category:

J Code

Tecvayli NDCs:

57894-0450-01, 57894-0449-01

Primary Type:

Oncology

Generic/Specialty Status:

Single-Source

Route of Administration:

Subcutaneous

Potential NDC Listing Errors:

Our team did not identify any potential listing errors/discrepancies for the NDCs mapped to this HCPCS code.

About Tecvayli:

TECVAYLI is a Oncology drug manufactured by Janssen Biotech, Inc. and administered via the Subcutaneous route of administration. The J Code: J9380 is aligned to the drug TECVAYLI.

TECVAYLI is an antineoplastic that belongs to the class of drugs known as monoclonal antibodies. This medication works by attaching to the CD3 protein on T cells and the other the part of the drug attached to the B cell maturation antigen. This helps the T cells target and kill cancer cells. TECVAYLI can be used to treat specific cancers of the bone marrow. This medication is manufactured by Janssen Biotech and is aligned to the HCPCS code J9380. Patient assistance programs for TECVAYLI can be found through the Janssen Patient Assistance Program.

ACCESS PRICING AND MORE BY REGISTERING

J9380 Added Date:

July 1, 2023

J9380 Effective Date:

July 1, 2023

J9380 Termination Date:

HCPCS Active

We have not yet identified a manufacturer source of Tecvayli billing and coding information.
Tecvayli patient assistance information can be found through Janssen CarePath at the URL: https://www.newprograminfo.com/
TECVAYLI prescribing information can be found at the link below:
Information regarding TECVAYLI’s side effects can be found at MedlinePlus